Results 281 to 290 of about 367,412 (367)

Clinical progress note: Rubella

open access: yesJournal of Hospital Medicine, Volume 21, Issue 2, Page 179-182, February 2026.
Visual Abstract Abstract Rates of rubella infection and congenital rubella syndrome decreased significantly since the introduction of the rubella vaccine in 1969. Endemic rubella was declared eliminated in the United States in 2004, and since 2012, all rubella cases in the United States have been associated with infections acquired abroad. With vaccine
Adam E. Gailani   +2 more
wiley   +1 more source

Giant Choledochal Cyst in a Child With Spinocerebellar Ataxia: A Potential Molecular Link Through Aberrant Cytosolic Calcium Signaling

open access: yes
American Journal of Medical Genetics Part A, Volume 200, Issue 3, Page 761-763, March 2026.
Hiromi Sumitomo   +3 more
wiley   +1 more source

Toward Dual‐Function Nanoparticle Platforms for Arboviral Diagnostics and Vaccines: Advances, Challenges, and Future Prospects

open access: yesNano Select, Volume 7, Issue 2, February 2026.
This review explores nanoparticle (NP)‐based biosensors and nanovaccine platforms for arboviral infections, highlighting their design, performance, and translational potential. By comparing case studies across viruses, it identifies gold‐standard nanomaterials such as gold NPs (AuNPs), zinc oxide NPs (ZnONPs), molybdenum disulfide (MoS2) nanocomposites,
Peyman Halvaeikhanekahdani   +3 more
wiley   +1 more source

IKAROS Associated Immunodeficiency and Thrombotic Thrombocytopenic Purpura

open access: yesPediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Pathogenic variants in IKZF1 (IKAROS) are linked to immunodeficiency, malignancy, and immune dysregulation. We describe a family with a rare IKZF1 variant presenting with humoral immunodeficiency and thrombotic thrombocytopenic purpura (TTP). A non‐consanguineous family was clinically monitored; clinical, immunological, and genetic data (exome
Ilia Spivak   +7 more
wiley   +1 more source

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials

open access: yesStatistics in Medicine, Volume 45, Issue 3-5, February 2026.
ABSTRACTCluster randomized trials (CRTs), in which entire clusters of subjects are randomized to treatment arms, are widely used in pragmatic trials to evaluate interventions under real‐world conditions. However, CRTs are particularly vulnerable to treatment non‐adherence, especially when cluster‐level preferences lead subjects in clusters to deviate ...
Yuwei Cheng   +2 more
wiley   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy